{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:34:03Z","timestamp":1790264043902,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NeoTract\/Teleflex, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Postoperative medication use is an important yet relatively unexplored element of the benign prostatic hyperplasia patient journey. We assessed and compared the percentage of patients who required medication postoperatively after the three most common BPH surgeries in the real world: transurethral resection of the prostate (TURP), photovaporization procedure with GreenLight Laser (PVP), and prostatic urethral lift (PUL) with the UroLift system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Within a random representative sample of US Medicare and commercial insurance claims, patients with at least one year of follow-up data available after an outpatient TURP, PVP, or PUL procedure were linked to pharmaceutical claims to elucidate rates of continuous and de novo use of alpha-blockers, 5-alpha reductase inhibitors, or combination medical therapy. Periods of interest were perioperative (use within three months postoperatively and not beyond) and one and five years postoperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      36 629 men diagnosed with BPH underwent outpatient TURP (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920 319), GreenLight PVP (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910 517) and PUL (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095 793) procedures within the claims dataset. The rate of medical therapy use through one year was lowest for PUL (4.1%) compared to TURP (6.2%) and PVP (6.6%), and was equivalent between procedures through five years (10.6% TURP, 10.4% PVP, and 10.3% PUL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients who undergo surgery to treat BPH may desire to discontinue or bypass BPH medications. However, these data demonstrated that approximately 10% of BPH patients used medication through five years postoperatively, regardless of which procedure they underwent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-025-00953-0","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:55:42Z","timestamp":1740729342000},"page":"913-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-7306","authenticated-orcid":false,"given":"Steven","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Ronald P.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Elterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0515-2578","authenticated-orcid":false,"given":"Bilal","family":"Chughtai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"953_CR1","doi-asserted-by":"crossref","unstructured":"Berry S, Coffey D, Walsh P &Ewing LL The Development of Human Benign Prostatic Hyperplasia with Age. J Urol. 132, 474\u20139 (1984)","DOI":"10.1016\/S0022-5347(17)49698-4"},{"key":"953_CR2","doi-asserted-by":"crossref","unstructured":"Roehrborn CG Benign prostatic hyperplasia: an overview. Rev Urol. S3-S14 (2005)","DOI":"10.1038\/ncpuro0553"},{"key":"953_CR3","doi-asserted-by":"crossref","unstructured":"AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 170, 530\u201347 (2003)","DOI":"10.1097\/01.ju.0000078083.38675.79"},{"key":"953_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/MOU.0000000000000007","volume":"24","author":"C Silva J","year":"2014","unstructured":"Silva J C, Silva CM, Cruz F. Current medical treatment of lower urinary tract symptoms\/BPH: do we have a standard? Curr Opin Urol. 2014;24:21\u20138.","journal-title":"Curr Opin Urol"},{"key":"953_CR5","first-page":"234","volume":"123","author":"RM Ren","year":"2010","unstructured":"Ren RM, Kou M, Lan XX. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis. Chin Med J. 2010;123:234\u20138.","journal-title":"Chin Med J"},{"key":"953_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","volume":"327","author":"GJ Gormley","year":"1992","unstructured":"Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl J Med. 1992;327:1185\u201391.","journal-title":"N. Engl J Med"},{"key":"953_CR7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl J Med. 2003;349:2387\u201398.","journal-title":"N. Engl J Med"},{"key":"953_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","volume":"60","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434\u201341.","journal-title":"Urology"},{"key":"953_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","volume":"68","author":"L Cindolo","year":"2015","unstructured":"Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68:418\u201325.","journal-title":"Eur Urol"},{"key":"953_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0302-2838(03)00376-2","volume":"44","author":"KM Verhamme","year":"2003","unstructured":"Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol. 2003;44:539\u201345.","journal-title":"Eur Urol"},{"key":"953_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","volume":"101","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101:17\u201321.","journal-title":"BJU Int"},{"key":"953_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/JU.0000000000001778","volume":"206","author":"KT McVary","year":"2021","unstructured":"McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021;206:715\u201324.","journal-title":"J Urol"},{"key":"953_CR13","first-page":"8802","volume":"24","author":"C Roehrborn","year":"2017","unstructured":"Roehrborn C, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802\u201313.","journal-title":"Can J Urol"},{"key":"953_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41391-023-00741-8","volume":"27","author":"S Kaplan","year":"2024","unstructured":"Kaplan S, Kaufman JRP, Mueller, Elterman D, Chughtai B, Rukstalis D, et al. Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study. Prosate Cancer Prostatic Dis. 2024;27:485\u201391.","journal-title":"Prosate Cancer Prostatic Dis"},{"key":"953_CR15","first-page":"10960","volume":"29","author":"PJ Gilling","year":"2022","unstructured":"Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol. 2022;29:10960\u20138.","journal-title":"Can J Urol"},{"key":"953_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5489\/cuaj.180","volume":"7","author":"JP Whelan","year":"2013","unstructured":"Whelan JP, Bowen JM, Burke N, Woods EA, McIssac GP, Hopkins RB, et al. A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada. Can Urol Assoc J. 2013;7:335\u201341.","journal-title":"Can Urol Assoc J"}],"updated-by":[{"DOI":"10.1038\/s41391-025-00982-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00953-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:06:48Z","timestamp":1764083208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00953-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00953-0","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-025-00982-9","URL":"https:\/\/doi.org\/10.1038\/s41391-025-00982-9","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Kaufman, Elterman, Chughtai, and Roehrborn are paid consultants for NeoTract\/Teleflex, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}